CD44 and breast cancer: mAbs against the CSC marker CD44 have been tested in preclinical models of BC (71), and the mAb-drug conjugate bivatuzumab mertansine, targeting CD44v6, has been tested in BC patients (NCT02254005, NCT02254031).